Experience

Aspec Association

• France
• Civic and Social Organizations
• 1 - 100 Employee

• ASPEC Scientific Advisory Board

  • Nov 2023 - 2 months



Pedriatric department Medical school

• Associate Professor at Université Laval

  • Sep 2023 - 4 months

  Québec, Canada



INSERM

• France
• Research Services
• 700 & Above Employee

• Research Director (DR2)

  • Aug 2016 - 7 years 5 months

  CIRI U1111 INSERM - UMR5308 CNRS - ENS Lyon - UCBL1

• Permanent researcher (CR1)

  • 2005 - Aug 2016

  CIRI U1111 INSERM - UMR5308 CNRS - ENS Lyon - UCBL1



CIRI U1111 INSERM - UMR5308 CNRS - ENS Lyon - UCBL1

• Co-Director - VirPath Laboratory

  • 2010 - 13 years

  Région de Lyon, France The Virpath laboratory proposes an integrative approach on a broad range of respiratory virus facets from surveillance to control. Our laboratory is organized in two interplaying teams (B Lina and M Rosa-Calatrava) and works on different aspects of respiratory virus biology, from the deciphering of the mechanisms leading to virus emergence and pathogenesis, to the analysis of viral interplays with cells and key host factors (including innate immune response) during respiratory virus infection… Show more The Virpath laboratory proposes an integrative approach on a broad range of respiratory virus facets from surveillance to control. Our laboratory is organized in two interplaying teams (B Lina and M Rosa-Calatrava) and works on different aspects of respiratory virus biology, from the deciphering of the mechanisms leading to virus emergence and pathogenesis, to the analysis of viral interplays with cells and key host factors (including innate immune response) during respiratory virus infection. In addition, a focus is done on the virus/bacteria co-infection issue and the host epithelium mucosal responses by using physiological and predictive preclinical models based on reconstructed human respiratory epithelium. In a more translational point of view, we are also interested in the mechanisms of antiviral resistance, as well as the discovery of innovative antiviral strategies targeting the host (drug repurposing) and optimization of vaccine quality and potency as new means to control influenza and pneumovirus infections. VirPath has strong connections with the National Respiratory Virus Reference Centre and the clinical research activities hosted by the Hospices Civils de Lyon. Importantly, a Technology Research Platform (VirNext) has been developed in order to enhance translational research and stimulate partnerships and transfer of technology towards the industry. Such connections resulted into a substantial portfolio of patents and transfers of technologies towards the industry, the implementation of several clinical trials, the conception of several partnership devices and the creation of four start-ups (VirHealth, Signia Therapeutics, Vaxxel, VirexpR). http://www.virpath.com/ https://www.virnext.fr/ https://virhealth.fr/ https://signiatherapeutics.com/en/ https://vaxxel.fr/ https://virexpr.fr/ Show less



International Associated Laboratory RespiVIR Université Claude Bernard Lyon 1 - Université Laval

• Co Director RespiVIR International Associated Laboratory

  • Jul 2021 - 2 years 6 months

  Lyon - Québec



AIS BIOTECH

• France
• Biotechnology Research
• 1 - 100 Employee

• Associate co-founder AIS Biotech

  • Mar 2023 - 10 months

  Grenoble, Auvergne-Rhône-Alpes, France AIS BIOTECH, created in March 2023, is the result of a collaboration initiated in 2018 between the Center for Research on Plant Macromolecules Cermav, an expert in scalable processes for the bio-production of complex polysaccharides, and our laboratory and its Technology Platform Research VirNext, who provided their expertise on pathogenic respiratory viruses and their preclinical models of infection in vitro and in vivo. This R&D partnership has resulted in the identification and validation at… Show more AIS BIOTECH, created in March 2023, is the result of a collaboration initiated in 2018 between the Center for Research on Plant Macromolecules Cermav, an expert in scalable processes for the bio-production of complex polysaccharides, and our laboratory and its Technology Platform Research VirNext, who provided their expertise on pathogenic respiratory viruses and their preclinical models of infection in vitro and in vivo. This R&D partnership has resulted in the identification and validation at the preclinical stage in vivo of Glycoflu, a first compound of a new class of therapeutic molecules against human Influenza viruses. Glycoflu is a synthetic complex glycopolymer resulting from a scalable process of bioproduction in the bacterium E. coli modified by metabolic engineering. These common results gave rise to the filing of a European patent entitled “New sialosides and their use in therapy” (EP21305131.1), protecting the compound, its bioproduction process and its therapeutic indication. AIS Biotech aims to develop a pipeline of innovative sugar-based biopharmaceuticals which can prevent or treat infections by mimicking the natural host surface oligosaccharide binding-sites of pathogens. Show less



VirexpR

• France
• Biotechnology Research
• 1 - 100 Employee

• Associate co-founder VirexpR

  • Jan 2022 - 2 years

  VirexpR proposes innovative technological offers and a wider range of R&D services in the field of Indoor Air Quality (IAQ). VirexpR is specialized in the generation of atmospheres contaminated by complex mixtures of infectious pathogens in test stands dedicated to the experimental performance evaluation of air treatment and respiratory protection technologies and devices. An offer of in situ sampling and analysis of indoor air will also be offered by VirexpR for a large panel of respiratory… Show more VirexpR proposes innovative technological offers and a wider range of R&D services in the field of Indoor Air Quality (IAQ). VirexpR is specialized in the generation of atmospheres contaminated by complex mixtures of infectious pathogens in test stands dedicated to the experimental performance evaluation of air treatment and respiratory protection technologies and devices. An offer of in situ sampling and analysis of indoor air will also be offered by VirexpR for a large panel of respiratory pathogenic viruses. In synergy with several of its providers and industrial partners in the Auvergne-Rhône-Alpes region, VirexpR will mobilize its expertise, technologies, and logistics in BSL-2 and BSL-3 facilities within the Lyonbiopole innovation center. This offer will be at the service of establishments open to the public (ERP), communities and manufacturers, in order to contribute to better control of respiratory viral pathogens and more generally to better indoor air quality, with major health, economic and societal implications and challenges. Show less



Centre Jacques Cartier

• France
• Events Services
• 1 - 100 Employee

• Membre du Comité de Programmation et de Prospective

  • Apr 2021 - 2 years 9 months



Vaxxel

• France
• Pharmaceutical Manufacturing
• 1 - 100 Employee

• Associate co-founder VAXXEL

  • Jul 2019 - 4 years 6 months

  Vaxxel is a spin-off of the Université Claude Bernard Lyon1 and the Virpath laboratory. Vaxxel is developping an innovative live attenuated bivalent vaccine candidate to fight pneumoviruses, which constitute major public health and socio-economic concerns (with more than 33 million children under 5 years old infected each year, resulting on average 3 million hospitalizations for acute respiratory infections, of which up to 1% to 2% are lethal). The technology of Vaxxel is based on the patented… Show more Vaxxel is a spin-off of the Université Claude Bernard Lyon1 and the Virpath laboratory. Vaxxel is developping an innovative live attenuated bivalent vaccine candidate to fight pneumoviruses, which constitute major public health and socio-economic concerns (with more than 33 million children under 5 years old infected each year, resulting on average 3 million hospitalizations for acute respiratory infections, of which up to 1% to 2% are lethal). The technology of Vaxxel is based on the patented polyvalent viral vaccine platform METAVAC® and a pilot upscalable process of production, using the proprietary DuckCelt®-T17 avian cell line. Show less



SIGNIA THERAPEUTICS

• France
• Research
• 1 - 100 Employee

• Associate co-founder SIGNIA THERAPEUTICS

  • May 2017 - 6 years 8 months

  Signia Therapeutics is a spin-off of Université Claude Bernard Lyon1. The company proposes an innovative and versatile platform for large spectrum antiviral drug discovery and repositioning based on globally targeting the host cell instead of specific viral molecular determinants. The innovative and proprietary platform will offer the minimization of drug resistance, with significant regulatory and financial benefits compared to the time-consuming and costly process of classical de novo… Show more Signia Therapeutics is a spin-off of Université Claude Bernard Lyon1. The company proposes an innovative and versatile platform for large spectrum antiviral drug discovery and repositioning based on globally targeting the host cell instead of specific viral molecular determinants. The innovative and proprietary platform will offer the minimization of drug resistance, with significant regulatory and financial benefits compared to the time-consuming and costly process of classical de novo molecule development. A Phase 2b trial fully funded will start in December 2018 for the evaluation of one very promising antiviral candidate in 176 Flu patients, with final results expected in 2020. Ongoing programs are currently conducted and dedicated to the identification and validation of broad-spectrum antiviral compounds against Flu, RSV, hMPV and human Coronaviruses. https://signiatherapeutics.com Show less



virnext

• France
• Biotechnology Research
• 1 - 100 Employee

• Co-founder and Director - VirNext Platform

  • Dec 2011 - 12 years 1 month

  VirNext is a spin-off (EZUS Lyon) of Université Claude Bernard Lyon 1 (UCBL1) created within the VirPath laboratory (Virology and human Pathologies, CIRI U1111 INSERM - UMR5308 CNRS - ENS Lyon - UCBL1) to foster industrial partnerships and enhance translational research. VirNext offers expertise in virology, notably influenza and other respiratory viruses, for the production of high-quality, deeply characterized viruses and viral vaccine antigens. With fully-functional BSL-2 and BSL-3 in-house… Show more VirNext is a spin-off (EZUS Lyon) of Université Claude Bernard Lyon 1 (UCBL1) created within the VirPath laboratory (Virology and human Pathologies, CIRI U1111 INSERM - UMR5308 CNRS - ENS Lyon - UCBL1) to foster industrial partnerships and enhance translational research. VirNext offers expertise in virology, notably influenza and other respiratory viruses, for the production of high-quality, deeply characterized viruses and viral vaccine antigens. With fully-functional BSL-2 and BSL-3 in-house facilities, our services also include complete in vitro and in vivo evaluation of antiviral and proviral molecules. http://www.virnext.fr/ Show less



VirPath

• Head of team "Molecular and Cellular of Influenza Signature, Vaccine and Antivirals"

  • 2010 - 13 years

  Région de Lyon, France Research activity of my team is focusing on two major axes: (i) the study of the functional interplay between respiratory pathogen viruses and the host cellular p53 pathway and (ii) the study of packaging and reassortment mechanisms of influenza viruses. http://www.virpath.com/molecular-and-cellular-signature-of-influenza-vaccine-and-antivirals/



Biovirsafe

• Director - Joint industrial Laboratory BIOVIRSAFE

  • Sep 2014 - Mar 2018

  Joint Research Laboratory Université Claude Bernard/VirPath - PSA BIOVIRSAFE is a joint research laboratory between VirPath and Produit Sanitaire Aéronef (PSA) SME (Labcom ANR program). BIOVIRSAFE is engaged in the control of contamination with different levels of constraints and requirements, notably in two major Public Health issues: (i) the protection of travellers’ health by limiting the emergence and worldwide dissemination of emerging diseases, and (ii) the minimization of nosocomial infections. BIOVIRSAFE develops new biocide formulations for surface… Show more BIOVIRSAFE is a joint research laboratory between VirPath and Produit Sanitaire Aéronef (PSA) SME (Labcom ANR program). BIOVIRSAFE is engaged in the control of contamination with different levels of constraints and requirements, notably in two major Public Health issues: (i) the protection of travellers’ health by limiting the emergence and worldwide dissemination of emerging diseases, and (ii) the minimization of nosocomial infections. BIOVIRSAFE develops new biocide formulations for surface disinfection and evaluates their potential for high-level decontamination by immersion and/or spray in both the aeronautic industry and the medical sector. The second aim of BIOVIRSAFE is to offer a new optimized biocide system and protocols for air disinfection in confined spaces for the industrial/medical sector. http://www.virpath.com/molecular-and-cellular-signature-of-influenza-vaccine-and-antivirals/biovirsafe/ Show less



Transgene

• France
• Biotechnology
• 100 - 200 Employee

• Project leader

  • 2001 - 2004

  Strasbourg Developpement of new armed and targeted oncolytic Ad vectors



IGBMC

• Research Services
• 200 - 300 Employee

• PhD

  • 1997 - 2001

  Team of Pr. C. Kédinger Characterization of the multifunctional activity of the adenovirus pIX protein